Stock comparison
ADMA Biologics
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ADMA
ADMA Biologics
Market cap
$1.91B
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ADMA | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 48D | 75B | IDXX |
| Benjamin Graham | 55D | 80A | IDXX |
| Philip Fisher | 59C | 75B | IDXX |
| Peter Lynch | 82C | 71B | ADMA |
| Joel Greenblatt | 46D | 83C | IDXX |
| Charlie Munger | 58D | 87A | IDXX |
| Terry Smith | 51C | 84A | IDXX |
Side-by-side metrics
| Metric | ADMA | IDXX |
|---|---|---|
| Market cap | $1.91B | $44.12B |
| P/E (TTM) | 12.0x | 39.0x |
| EV/EBIT | 10.5x | 31.6x |
| ROIC (TTM) | 27.81% | 40.66% |
| Gross margin | 61.27% | 62.05% |
| Net margin | 32.43% | 24.63% |
| Revenue CAGR 5y | 58.45% | 7.56% |
| EPS CAGR 5y | - | 10.79% |
| Debt / Equity | 0.5x | 0.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ADMA leads on
- Revenue CAGR 5y58.45%vs 7.56%+87%
- P/E (TTM)12.0xvs 39.0x+69%
- EV/EBIT10.5xvs 31.6x+67%
- Debt / Equity0.5xvs 0.7x+24%
IDXX leads on
- Market cap$44.12Bvs $1.91B+96%
- ROIC (TTM)40.66%vs 27.81%+32%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.